WaveMan
WaveMan · Company
ANIP · Ani Pharmaceuticals Inc
> Search tickers & screens ⌘K
LIVE
← All companies

ANIP ANI Pharmaceuticals (ANIP) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001023024
Quote by TradingView
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
177
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $328.0K priced

What the filings say about ANIP

Insiders, 180 days
-$9.0M net sold
8 sellers · 35% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.7M
5 notices

ANI Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ANI PHARMACEUTICALS INC insiders sold a net $9.0M of stock across 205 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Lalwani Nikhil
PRESIDENT & CEO
SELL
2026-10-16 SECtraded 2026-10-15
5,400
$388.2K
-1.9%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (1 buy, 11 sales), the last on Sep 15, 2026.
  • The trade is 1.6% of the 333,689 shares held after it.
  • 2 other insiders sold within 30 days.
  • 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT & CEO Lalwani Nikhil sold about $388.2K of ANIP under a 10b5-1 plan on Oct 15, 2026; 2 other insiders sold within 30 days and 177 funds added in the latest 13F quarter.
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
SELL
2026-10-13 SEC
500
$36.8K
+1.4%
Context
  • 35 earlier Form 4 trades (code P or S) here by this insider (35 sales), the last on Sep 14, 2026.
  • The trade is 0.7% of the 73,424 shares held after it.
  • 2 other insiders sold within 30 days.
  • 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold about $36.8K of ANIP under a 10b5-1 plan on Oct 13, 2026; 2 other insiders sold within 30 days and 177 funds added in the latest 13F quarter.
CAREY STEPHEN P.
SVP & CFO
SELL
2026-09-30 SECtraded 2026-09-29
2,850
$208.1K
-2.5%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Aug 31, 2026.
  • The trade is 1.7% of the 168,993 shares held after it.
  • 3 other insiders sold within 30 days.
  • 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & CFO CAREY STEPHEN P. sold about $208.1K of ANIP under a 10b5-1 plan on Sep 29, 2026; 3 other insiders sold within 30 days and 177 funds added in the latest 13F quarter.
Lalwani Nikhil
PRESIDENT & CEO
SELL
2026-09-16 SECtraded 2026-09-15
5,400
$383.4K
-5.6%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (1 buy, 10 sales), the last on Aug 25, 2026.
  • The trade is 1.6% of the 339,089 shares held after it.
  • 3 other insiders sold within 30 days.
  • 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT & CEO Lalwani Nikhil sold about $383.4K of ANIP under a 10b5-1 plan on Sep 15, 2026; 3 other insiders sold within 30 days and 177 funds added in the latest 13F quarter.
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
SELL
2026-09-14 SEC
500
$35.4K
-1.3%
Context
  • 34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Aug 13, 2026.
  • The trade is 0.7% of the 73,924 shares held after it.
  • 3 other insiders sold within 30 days.
  • 177 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold about $35.4K of ANIP under a 10b5-1 plan on Sep 14, 2026; 3 other insiders sold within 30 days and 177 funds added in the latest 13F quarter.
205 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 200 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$9.0M over 180 days
-$2.2M over 90 days
below 83% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
177 funds bought in last quarter
more than 87% of Pharma & Biotech
Revenue
+43.8% year over year
more than 74% of Pharma & Biotech
Margin
8.9% net margin
more than 81% of Pharma & Biotech
Buybacks
$20.6M repurchased, FY to 2026-06-30
below 60% of Pharma & Biotech
Short interest
17.8% of the float short (float per yahoo 2026-10-26) · 7.2 days to cover · settled 2026-09-30
What changed in the last 30 days
Oct 16PRESIDENT & CEO Lalwani Nikhil sold $388.2K under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 15Director NIKHIL LALWANI filed to sell $378.9K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 13SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $36.8K under a 10b5-1 plan (Oct 13)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 30SVP & CFO CAREY STEPHEN P. sold $208.1K under a 10b5-1 plan (Sep 29)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch ANIP

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-25.0%12M
-26%-17%-9%+0%2025-102025-122026-022026-042026-062026-082026-10 2026-05-11 · Lalwani Nikhil sold $4.3M2025-11-12 · Gassert Chad sold $1.3M2026-05-13 · Walsh Patrick D sold $806.3K2025-11-13 · Walsh Patrick D sold $750.9K2026-02-12 · Mutz Christopher sold $538.3K2026-03-03 · Walsh Patrick D sold $445.4K2026-02-20 · Mutz Christopher sold $415.3K2026-08-25 · Lalwani Nikhil sold $401.2K2026-10-15 · Lalwani Nikhil sold $388.2K2026-09-15 · Lalwani Nikhil sold $383.4K2026-03-09 · Davis Krista sold $377.1K2026-03-11 · Rowland Thomas Andrew sold $357.5K2026-05-11 · Walsh Patrick D sold $320.8K2026-03-05 · CAREY STEPHEN P. sold $302.2K2026-07-02 · CAREY STEPHEN P. sold $284.9K2026-03-09 · Mutz Christopher sold $267.2K2026-06-05 · CAREY STEPHEN P. sold $265.0K2026-03-05 · CAREY STEPHEN P. sold $249.8K2026-08-10 · Gutwerg Ori sold $243.5K2026-06-29 · CAREY STEPHEN P. sold $239.7K2026-07-29 · CAREY STEPHEN P. sold $231.9K2026-03-13 · Mutz Christopher sold $226.5K2026-05-12 · Gutwerg Ori sold $220.4K2026-09-29 · CAREY STEPHEN P. sold $208.1K2026-08-31 · CAREY STEPHEN P. sold $207.5K2026-06-08 · HAUGHEY THOMAS sold $161.8K2026-02-19 · Davis Krista sold $161.6K2026-03-03 · Gutwerg Ori sold $157.6K2026-03-06 · Mutz Christopher sold $157.4K2025-12-05 · TANNENBAUM RENEE P sold $146.1K2026-02-20 · Davis Krista sold $134.9K2025-12-18 · Davis Krista sold $133.7K2026-03-06 · Davis Krista sold $111.4K2026-09-11 · Thoma Jeanne sold $71.5K2026-01-13 · Cook Meredith sold $42.2K2026-06-12 · Cook Meredith sold $41.0K2026-07-13 · Cook Meredith sold $40.9K2026-05-13 · Cook Meredith sold $39.1K2026-04-13 · Cook Meredith sold $39.0K2026-02-13 · Cook Meredith sold $38.4K2026-08-13 · Cook Meredith sold $37.7K2026-10-13 · Cook Meredith sold $36.8K2026-10-15 · NIKHIL LALWANI filed to sell $378.9K2026-09-15 · NIKHIL LALWANI filed to sell $380.2K2026-09-11 · JEANNE THOMA filed to sell $71.5K2026-08-25 · NIKHIL LALWANI filed to sell $400.5K2026-07-29 · STEPHEN P CAREY filed to sell $499.4K2026-07-07 · PATRICK WALSH filed to sell $373.7K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ANIP: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
2,958,646 sh
$244.9M
Soleus Capital Management, L.P.
867,760 sh
$71.8M
VANGUARD CAPITAL MANAGEMENT LLC
838,224 sh
$69.4M
STATE STREET CORP
831,647 sh
$68.9M
TANG CAPITAL MANAGEMENT LLC
707,500 sh
$58.6M

Congress trades in ANIP

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ANIP planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
NIKHIL LALWANI
Filed 2026-10-15
$378.9K
NIKHIL LALWANI
Filed 2026-09-15
$380.2K
JEANNE THOMA
Filed 2026-09-11
$71.5K
NIKHIL LALWANI
Filed 2026-08-25
$400.5K
STEPHEN P CAREY
Filed 2026-07-29
$499.4K

ANIP mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
abrdn U.S. Small Cap Equity Fund
$10.6M position · as of 2026-07-31
2.7%
Invesco Pharmaceuticals ETF
$12.0M position · as of 2026-07-31
2.5%
Ranger Micro Cap Fund
$282.1K position · as of 2026-07-31
2.4%
Miller Convertible Total Return ETF
$315.2K position · as of 2026-07-31
2.2%
abrdn Focused U.S. Small Cap Active ETF
$218.9K position · as of 2026-07-31
2.2%
TETON Convertible Securities Fund
$259.4K position · as of 2026-06-30
1.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $9.0M sold by insiders over 180 days, 177 funds added last quarter, $1.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ANIP financials

Revenue growth
+43.8%
XBRL, annual
Net margin
8.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$978.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+11.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$173.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.50x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.63x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
+20.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+7.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+21.6%
operating income after a 24.0% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+13.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
15.37x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$883.4M$614.4M$486.8M$316.4M
Operating income$111.1M$584.0K$47.0M-$35.3M
Net income$78.0M-$19.0M$19.0M-$48.0M
EPS (diluted)3.32-1.040.85-3.05
Operating cash flow$185.2M$64.0M$119.0M-$31.2M
Cash$285.6M$144.9M$221.1M$48.2M
Long-term debt$291.8M$309.1M$284.8M$285.7M
Buybacks$12.2M$11.0M$5.0M$2.0M
Dividends paid$1.2M$1.6M$1.6M$1.6M
SEC XBRL, fiscal years, as known on 2026-10-28

ANIP Stock Sonar score 6/7 axes

Find similar shapesCompare

ANIP ranks highest on institutional and government (87th percentile) and profitability (82nd), and lowest on insider conviction (8th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
82
Inputs
  • Return on equity+20.9% · 89 pct, sector of 545
  • Return on assets+7.6% · 88 pct, sector of 691
  • Return on invested capital+21.6% · 61 pct, sector of 45
  • Return on capital employed+13.0% · 91 pct, sector of 576
Financial health
61
Inputs
  • Debt to equity0.50x · 31 pct, sector of 352
  • Cash flow to debt0.63x · 90 pct, sector of 371
Growth
74
Inputs
  • Revenue growth, YoY+43.8% · 74 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
8
Inputs
  • Net Form 4 buying (codes P and S), 180d-$7.2M · 16 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
87
Inputs
  • Funds adding, latest quarter177 · 87 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
16
Inputs
  • Short interest, % of float+17.8% · 19 pct, sector of 813
  • Recalls per $1B revenue, 3y2.26 per $1B · 18 pct, universe of 292
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+26.4% · 10 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ANIP filings, in plain words

Are ANI Pharmaceuticals insiders buying or selling ANIP?

In the 180 days to 2026-10-28, ANI Pharmaceuticals insiders were net sellers, a net $9.0M across purchases and sales reported on Form 4, by 8 sellers.

Are there planned insider sales of ANIP?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.7M of stock; the latest, by NIKHIL LALWANI, was filed 2026-10-15.

Read the full summary

In the 180 days to 2026-10-28, ANI Pharmaceuticals insiders were net sellers of ANIP, a net $9.0M across purchases and sales reported on Form 4 by 8 sellers. 35% of the 23 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies